(Q37579230)

21 August 2017

1 reference

title

Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue (English)

1 reference

21 August 2017

1

Kjetil Retterstøl

1 reference

PubMed ID

19678802

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

1 reference

21 August 2017

18

1 reference

21 August 2017

9

1 reference

21 August 2017

1405-1411

1 reference

Obesity and diabetes in the developing world--a growing challenge

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

PPARgamma and its ligands: therapeutic implications in cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Cardiovascular effects of thiazolidinediones: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

The role of gut hormones in glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Nutritional regulation of glucagon-like peptide-1 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

[2008: the end of rimonabant's story].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Incretin-based therapies in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

Distribution and regulation of protein expression of the free fatty acid receptor GPR120.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903164205

10.1517/13543780903164205

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19678802